Back

Senolytics Restore Hematopoietic Stem Cells Function in Sickle Cell Disease

Barve, A.; Cornwell, A.; Sriram, P.; Kopyov, A.; Dabas, P.; Kooienga, E.; Kelley, Z.; Johnson, J.; Myers, J.; Obeng, E.; Kang, G.; Olufadi, Y.; Cain, T.; Talbot, L.; Spence, D.; Cortes, M.; Miller, S.; Loeffler, D.; Sharma, A.; McKinney-Freeman, S.

2025-02-09 cell biology
10.1101/2025.02.08.636742 bioRxiv
Show abstract

Sickle Cell Disease (SCD) is a blood disorder affecting millions worldwide. Emerging evidence reveals that SCD pathophysiology increases risk of myeloid malignancies and hematopoietic stem cell (HSC) dysfunction, possibly due to pathological stress on bone marrow. To investigate this further, we interrogated mice and individuals with SCD and observed extended cell cycle times, oxidative stress, DNA damage, senescence, and dysregulation of molecular programs associated with these processes in bone marrow hematopoietic stem and progenitor cells (HSPCs). Human SCD HSPCs displayed poor hematopoietic potential ex vivo. SCD mice displayed a dramatic loss of transplantable bone marrow HSPCs, which was reversed upon treatment of SCD mice with the senolytic agent, ABT-263 (navitoclax). Thus, senolytics restore bone marrow function during SCD in mice and represent a novel strategy to improve bone marrow health in individuals with SCD and improve the safety of potentially curative gene therapies that utilize autologous HSPCs from individuals with SCD.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.